- Home
- ASTC vs SABS Comparison
ASTC vs SABS Comparison
Compare ASTC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- SABS
- Stock Information
- Founded
- ASTC 1984
- SABS 2014
- Country
- ASTC United States
- SABS United States
- Employees
- ASTC N/A
- SABS N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- SABS Health Care
- Exchange
- ASTC Nasdaq
- SABS Nasdaq
- Market Cap
- ASTC 11.0M
- SABS 11.4M
- IPO Year
- ASTC 1995
- SABS N/A
- Fundamental
- Price
- ASTC $5.91
- SABS $1.75
- Analyst Decision
- ASTC
- SABS Strong Buy
- Analyst Count
- ASTC 0
- SABS 5
- Target Price
- ASTC N/A
- SABS $11.40
- AVG Volume (30 Days)
- ASTC 2.8K
- SABS 25.4K
- Earning Date
- ASTC 05-12-2025
- SABS 05-19-2025
- Dividend Yield
- ASTC N/A
- SABS N/A
- EPS Growth
- ASTC N/A
- SABS N/A
- EPS
- ASTC N/A
- SABS N/A
- Revenue
- ASTC $419,000.00
- SABS $1,322,410.00
- Revenue This Year
- ASTC N/A
- SABS N/A
- Revenue Next Year
- ASTC N/A
- SABS $50.00
- P/E Ratio
- ASTC N/A
- SABS N/A
- Revenue Growth
- ASTC N/A
- SABS N/A
- 52 Week Low
- ASTC $5.74
- SABS $1.00
- 52 Week High
- ASTC $12.29
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- ASTC 41.25
- SABS 63.35
- Support Level
- ASTC $5.87
- SABS $1.30
- Resistance Level
- ASTC $6.09
- SABS $1.49
- Average True Range (ATR)
- ASTC 0.18
- SABS 0.14
- MACD
- ASTC 0.00
- SABS 0.06
- Stochastic Oscillator
- ASTC 23.94
- SABS 100.00
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.